Literature DB >> 2878461

Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788.

T Duka, M Ackenheil, J Noderer, A Doenicke, R Dorow.   

Abstract

Noradrenaline (NA) plasma levels were examined in 18 healthy volunteers on 2 consecutive days after a single treatment with either lormetazepam (0.06 mg/kg) (LMZ group), flunitrazepam (0.03 mg/kg) (FNZ group) or placebo (PLA group) in combination with the benzodiazepine (BZ) antagonist Ro 15-1788 (0.1 mg/kg). Behavioural responses (mood changes, anxiety) were also investigated in parallel. Both BZ decreased NA plasma levels to 50% of the basal values 10 min after the injection; administration of Ro 15-1788 15 min later reinstated NA plasma levels to basal values. A second administration of Ro 15-1788 (0.1 mg/kg) 24 h after BZ or PLA treatment increased NA plasma levels, estimated 10 min after the injection in both the LMZ- and the FNZ groups, but not in the PLA group. Behavioural responses measured under the same treatment also indicated minor anxiety responses followed by mood impairment. These data suggest that a stressful situation may be precipitated by the antagonist Ro 15-1788 24 h after a single BZ treatment, which resembles a withdrawal response, and increases NA plasma levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878461     DOI: 10.1007/bf00179190

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  Excretion of epinephrine and norepinephrine in various emotional states.

Authors:  F ELMADJIAN; J M HOPE; E T LAMSON
Journal:  J Clin Endocrinol Metab       Date:  1957-05       Impact factor: 5.958

2.  Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.

Authors:  A Darragh; R Lambe; M Scully; I Brick; C O'Boyle; W W Downe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

3.  Anxiogenic aspects of diazepam withdrawal can be detected in animals.

Authors:  M Emmett-Oglesby; D Spencer; M Lewis; F Elmesallamy; H Lal
Journal:  Eur J Pharmacol       Date:  1983-08-19       Impact factor: 4.432

4.  The action of stress, beta-carbolines, diazepam, and Ro 15-1788 on GABA receptors in the rat brain.

Authors:  G Biggio
Journal:  Adv Biochem Psychopharmacol       Date:  1983

5.  The role of the central noradrenergic nervous system in the mediation of the ethanol intoxication and ethanol withdrawal syndrome.

Authors:  L F Major; R J Hawley; M Linnoila
Journal:  Psychopharmacol Bull       Date:  1984

6.  Withdrawal from long-term benzodiazepine treatment.

Authors:  H Petursson; M H Lader
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-05

7.  Effects of diazepam premedication and epinephrine-containing local anesthetic on cardiovascular and plasma catecholamine responses to oral surgery.

Authors:  R A Dionne; D S Goldstein; P R Wirdzek
Journal:  Anesth Analg       Date:  1984-07       Impact factor: 5.108

8.  Sedative and cardiovascular effects of clonidine and nitrazepam.

Authors:  V Hossmann; T J Maling; C A Hamilton; J L Reid; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

9.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

10.  Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

Authors:  U Klotz; T Duka; R Dorow; A Doenicke
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

View more
  11 in total

1.  Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity.

Authors:  T Duka; D N Stephens; W Krause; R Dorow
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

Review 3.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects.

Authors:  T Duka; D Goerke; R Dorow; L Höller; K Fichte
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 5.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

6.  Plasma catecholamine concentration during sedation in ventilated patients requiring intensive therapy.

Authors:  K L Kong; S M Willatts; C Prys-Roberts; J T Harvey; S Gorman
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

7.  Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects.

Authors:  E D Risby; J K Hsiao; R N Golden; W Z Potter
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Effects of lorazepam on cardiac vagal tone during rest and mental stress: assessment by means of spectral analysis.

Authors:  J H Tulen; G Mulder; L Pepplinkhuizen; A J Man in 't Veld; H G van Steenis; P Moleman
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 9.  Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).

Authors:  U Klotz; J Kanto
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

10.  Dose-dependent effects of intravenous lorazepam on cardiovascular activity, plasma catecholamines and psychological function during rest and mental stress.

Authors:  J H Tulen; P Moleman; F Boomsma; H G van Steenis; V J van den Heuij
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.